In Defense of Risk | GenomeWeb

In Defense of Risk

Like most investors, federal funding agencies tend to view risk negatively when it comes to research — they want to see proof before digging into their pockets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

An Eye on the Bugs

Move Things Around

A Lab at Home

Genetic Roots

Da Vinci's Code

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.